Skip to main content
Premium Trial:

Request an Annual Quote

Luminex's Q4 Revenues Climb 51 Percent as Profit Rises on Settlement

NEW YORK (GenomeWeb News) – Luminex today reported a 51 percent increase in fourth-quarter revenues and a sharp uptick in profits, due to a settlement payment received during the quarter.
 
The results include the combined operations of Luminex and Tm Bioscience, which Luminex acquired for $44 million last March and renamed Luminex Molecular Diagnostics.
 
The Austin, Texas-based firm reported revenue of $21.5 million for the three months ended Dec. 31, up from revenues of $14.2 million in the fourth quarter of 2006.
 
Revenues for the Technology Group, which consists of sales of systems and beads, royalties, service, and support, were $18.6 million for the quarter, compared to $14.2 million in the comparable quarter a year ago. Revenues for the Assay Group, which consists of assays sold by Luminex Molecular Diagnostics and the Luminex Bioscience Group, were $4.1 million for the quarter compared to virtually no revenue the year before.
 
The company shipped 250 of its xMAP multiplex instruments during the fourth quarter, bringing its total installed base of instruments to 4,979 at the end of the year.
 
Luminex’s fourth-quarter net income was $11.1 million, or $.31 per share, compared to $600,000, or $.02 per share, in Q4 last year. This year’s profit is attributable to an $11.5 million payment the firm received during the quarter for settlement of litigation with Rules Based Medicine.
 
The firm’s R&D costs climbed 83 percent to $4.3 million in the quarter versus $2.3 million last year, while its SG&A expenses jumped 92 percent year over year to $11.9 million from $6.2 million.
 
During the quarter, Luminex launched its FlexmiR Select microRNA assay and received US Food and Drug Administration clearance to sell its xTAG Respiratory Virus Panel.
 
For full-year 2007, Luminex reported revenues of $75 million versus $53 million in 2006, a 41.5 percent increase. The firm posted a net loss of $2.7 million, or $.08 per share, for the year, compared to a profit of $1.5 million, or $.05 per share, in 2006.
 
Luminex’s R&D expenses for the year rose 77 percent to $15.4 million from $8.7 million, while SG&A costs were up 68 percent to $40.7 million from $24.2 million.
 
Luminex finished the year with $27.2 million in cash and cash equivalents.
 
The firm expects full-year 2008 revenue to be in the range of $95 million to $105 million.
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.